Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 4Neuroblastoma 2Neoplasms 2Fatigue 2Colorectal Neoplasms 2Wilms Tumor 1Thromboembolism 1Squamous Cell Carcinoma of Head and Neck 1Skin Abnormalities 1Salivary Gland Neoplasms 1Radiation Injuries 1Polycystic Ovary Syndrome 1Pain 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Depression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Blood Specimen Collection 14Nivolumab 13Ipilimumab 12pembrolizumab 11trametinib 9Surveys and Questionnaires 9Gene Expression Profiling 9dabrafenib 8Biopsy 6Specimen Handling 5Immunotherapy 5Immunohistochemistry 5Amplified Fragment Length Polymorphism Analysis 4encorafenib 3binimetinib 3atezolizumab 3Restraint, Physical 3Quality of Life 3Polymerase Chain Reaction 3Introns 3Flow Cytometry 3Drug Therapy 3Data Collection 3tremelimumab 2pimonidazole 2cobimetinib 2aldesleukin 2Watchful Waiting 2Vemurafenib 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Melanoma × Enzyme-Linked Immunosorbent Assay × Clear all
NCT01489423 2017-05-17

Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim

Eastern Cooperative Oncology Group

Completed
270 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡